Evidence map›Paper›PMID 42178601›Full record

SynthesisJournal of cellular and molecular medicine2026

Oncogenic Role of SRPK2 in Different Types of Cancer: A Systematic Review.

Samuel Inácio da Silva Paiva, Bárbara Braga Ferreira, Alexandre Martins Oliveira Portes, Sebastião Felipe Ferreira Costa, Luiz Otávio Guimarães Ervilha, Raoni Pais Siqueira, Juliana Regina Ribeiro de Souza, Luciana Ângelo de Souza, Gustavo Costa Bressan

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Samuel Inácio da Silva PaivaDepartamento de Bioquímica e Biologia Molecular, Universidade Federal de Viçosa, Viçosa, Minas Gerais, Brazil.
Bárbara Braga FerreiraDepartamento de Bioquímica e Biologia Molecular, Universidade Federal de Viçosa, Viçosa, Minas Gerais, Brazil.
Alexandre Martins Oliveira PortesDepartamento de Educação Física, Universidade Federal de Viçosa, Viçosa, Minas Gerais, Brazil.
Sebastião Felipe Ferreira CostaDepartamento de Educação Física, Universidade Federal de Viçosa, Viçosa, Minas Gerais, Brazil.
Luiz Otávio Guimarães ErvilhaDepartamento de Biologia Geral, Universidade Federal de Viçosa, Viçosa, Minas Gerais, Brazil.ORCID 0000-0001-6355-2492
Raoni Pais SiqueiraDepartamento de Bioquímica e Biologia Molecular, Universidade Federal de Viçosa, Viçosa, Minas Gerais, Brazil.
Juliana Regina Ribeiro de SouzaDepartamento de Bioquímica e Biologia Molecular, Universidade Federal de Viçosa, Viçosa, Minas Gerais, Brazil.
Luciana Ângelo de SouzaDepartamento de Bioquímica e Biologia Molecular, Universidade Federal de Viçosa, Viçosa, Minas Gerais, Brazil.
Gustavo Costa BressanDepartamento de Bioquímica e Biologia Molecular, Universidade Federal de Viçosa, Viçosa, Minas Gerais, Brazil.ORCID 0000-0002-9741-4554

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 311163/2022-0Conselho Nacional de Desenvolvimento Científico e Tecnológico 408484/2024-1Coordenação de Aperfeiçoamento de Pessoal de Nível Superior 001Fundação de Amparo à Pesquisa do Estado de Minas Gerais APQ-01084-21Fundação de Amparo à Pesquisa do Estado de Minas Gerais APQ-05143-23Fundação de Amparo à Pesquisa do Estado de Minas Gerais BPD-00827-22Fundação de Amparo à Pesquisa do Estado de Minas Gerais RED-00067-23Fundação de Amparo à Pesquisa do Estado de Minas Gerais RED00096-22
6 · The paper itself

Abstract

A systematic review was conducted to evaluate the available evidence regarding the tumorigenic and metastatic roles of serine/arginine protein kinase 2 (SRPK2) across different cancer types. A range of preclinical studies was included, generally addressing four main aspects: cancer-related signalling pathways involving SRPK2; its prognostic associations; its impact on metastatic and/or tumour phenotypes; and the antitumor and/or antimetastatic effects resulting from its inhibition. Here, we summarise and discuss the mechanisms through which SRPK2 exerts its oncogenic functions, as well as the therapeutic potential of targeting this kinase. SRPK2 may promote cancer development through its canonical role in alternative splicing, as well as through its involvement in diverse cellular signalling pathways. Moreover, elevated SRPK2 expression across multiple human malignancies consistently correlates with poor clinical outcomes. Collectively, these findings highlight SRPK2 as a promising therapeutic target and potential tumour biomarker.

Indexed as

CarcinogenesisNeoplasmsOncogenesProtein Serine-Threonine KinasesAlternative SplicingAnimalsBiomarkers, TumorGene Expression Regulation, NeoplasticHumansSignal TransductionBiomarkers, TumorProtein Serine-Threonine KinasesSRPK2 protein, humancancermetastasisserine/arginine protein kinase 2 (SRPK2)targeted therapytumour

Identifiers

PMID42178601
PMCPMC13239542

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.